Schizophrenia - Pipeline Review, H1 2017
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia - Pipeline Review, H1 2017, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape.
Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. Risk factors inc
Read More
- List of Tables
- Number of Products under Development for Schizophrenia, H1 2017
- Number of Products under Development by Companies, H1 2017
- Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
- Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
- Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
- Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
- Number of Products under Development by Univer
Read More
- Table of Contents
- Table of Contents 2
- Introduction 6
- Schizophrenia - Overview 7
- Schizophrenia - Therapeutics Development 8
- Schizophrenia - Therapeutics Assessment 24
- Schizophrenia - Companies Involved in Therapeutics Development 36
- Schizophrenia - Drug Profiles 73
- Schizophrenia - Dormant Projects 274
- Schizophrenia - Discontinued Products 282
- Schizophrenia - Product Development Milestones 285
- Appendix 295
Read More